Anti-Mullerian Hormone According to Polycystic Ovary Syndrome Phenotypes

Authors : Serkan Polat, Osmna Nuri Erginay

Pages : 77-84

Doi:10.46969/EZH.1482404

View : 88 | Download : 97

Publication Date : 2024-09-26

Article Type : Research Paper

Abstract :Objective: The aim of this study was to investigate the level of antimullerian hormone in patients with polycystic ovary syndrome (PCOS) according to phenotypic characteristics. Materials and Methods: This study was designed as a cross-sectional cohort study and included patients attending the PCOS clinic of Etlik Zübeyde Hanım Gynecology Training and Research Hospital. Anti-mullerain hormone (AMH) levels were recorded according to phenotype assessment. Results: A total of 118 patients with PCOS participated in the study. Accordingly, 47 patients (39.8%) belonged to phenotype A, 15 patients (12.7%) to phenotype B, 37 patients (31.3%) to phenotype C and 19 patients (16.1%) to phenotype D. The mean age of the patients was 22.97±4.98 years. The mean body mass index was 26.1± 4.26 kg/m2. The most common reason for presentation to the PCOS outpatient clinic was irregular menstruation. The most common reason for presentation to the PCOS outpatient clinic was irregular menstruation in phenotype A (80.9%) and phenotype D (84.2%). There was a difference between the groups in the distribution of the presence of polycystic ovarian morphology (PCOM) and the frequency of ovarian dysfunction by phenotype (p<0.001, p<0.001). A statistically significant difference was found between median AMH levels (ng/ml) according to phenotype (p<0.001). The median value was 6.3 ng/ml in phenotype A, 2.4 ng/ml in phenotype B, 6.1 ng/ml in group C and 6.6 ng/ml in phenotype D. Conclusion: In our study, phenotype A was the most frequently observed group and AMH levels were significantly higher in the phenotype D group than in the other groups.
Keywords : Fenotip, polikistik over sendromu, anti müllerian hormon, Ferriman Gallwey skoru

ORIGINAL ARTICLE URL